NXL101

Synonym(s): AVE 4221  |  viquidacin

Class: Quinolone

Spectrum of activity:	Gram-negative
Details of activity:	Was in trials for treatment of MRSA and nosocomial infections
Description:	Levasseur P, Delachaume C, Lowther J, Hodgson J. Minimum inhibitory concentrations and mutation prevention concentrations of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;184
Institute where first reported:	Novexel (Astrazeneca, UK)
Year first mentioned:	2005
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	In phase I trials, QT elongation was seen in patients so was dropped for safety reasons (2)

Chemical structure(s):
Canonical SMILES:	COC1=CC=C2C(=C1)C(=C(C=N2)F)[C@H](CC[C@@H]3CCN(CCSC4=CC=CS4)C[C@@H]3C(=O)O)O
Isomeric SMILES:	COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)CCSC4=CC=CS4)O
InChI:	InChI=1S/C25H29FN2O4S2/c1-32-17-5-6-21-18(13-17)24(20(26)14-27-21)22(29)7-4-16-8-9-28(15-19(16)25(30)31)10-12-34-23-3-2-11-33-23/h2-3,5-6,11,13-14,16,19,22,29H,4,7-10,12,15H2,1H3,(H,30,31)/t16-,19+,22+/m1/s1
InChI Key:	USGHRRVFKSLEJT-WVBUVRCRSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/11591505

External links:
Guide to Pharmacology:	viquidacin
Citation:	https://www.biospace.com/article/releases/novexel-discontinues-development-of-nxl-101-/